BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 12176790)

  • 1. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model.
    Hollender A; Kvaloy S; Nome O; Skovlund E; Lote K; Holte H
    Ann Oncol; 2002 Jul; 13(7):1099-107. PubMed ID: 12176790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Boehme V; Zeynalova S; Kloess M; Loeffler M; Kaiser U; Pfreundschuh M; Schmitz N
    Ann Oncol; 2007 Jan; 18(1):149-157. PubMed ID: 17018708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of Central Nervous System (CNS) Involvement in Children With Non-Hodgkin's Lymphoma (NHL) and the Diagnostic Value of CSF Flow Cytometry in CNS Positive Disease.
    Huang S; Jin L; Yang J; Duan Y; Zhang M; Zhou C; Zhang YH
    Technol Cancer Res Treat; 2021; 20():15330338211016372. PubMed ID: 34060372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
    Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
    Cancer; 2002 Aug; 95(3):576-80. PubMed ID: 12209750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
    Salzburg J; Burkhardt B; Zimmermann M; Wachowski O; Woessmann W; Oschlies I; Klapper W; Wacker HH; Ludwig WD; Niggli F; Mann G; Gadner H; Riehm H; Schrappe M; Reiter A
    J Clin Oncol; 2007 Sep; 25(25):3915-22. PubMed ID: 17761975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma.
    Chua SL; Seymour JF; Streater J; Wolf MM; Januszewicz EH; Prince HM
    Leuk Lymphoma; 2002 Sep; 43(9):1783-8. PubMed ID: 12685832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis.
    Hollender A; Kvaloy S; Lote K; Nome O; Holte H
    Eur J Cancer; 2000 Sep; 36(14):1762-8. PubMed ID: 10974623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era.
    Sancho JM; Orfao A; Quijano S; García O; Panizo C; Pérez-Ceballos E; Deben G; Salar A; González-Barca E; Alonso N; García-Vela JA; Capote J; Peñalver FJ; Provencio M; Arias J; Plaza J; Caballero D; Morado M; Feliu E; Ribera JM;
    Eur J Haematol; 2010 Oct; 85(4):321-8. PubMed ID: 20528905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central nervous system involvement in T-cell lymphoma: A single center experience.
    Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
    Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations.
    Tomita N; Kodama F; Sakai R; Koharasawa H; Hattori M; Taguchi J; Fujita H; Tanabe J; Fujisawa S; Fukawa H; Harano H; Kanamori H; Miyashita H; Matsuzaki M; Ogawa K; Motomura S; Maruta A; Ishigatsubo Y
    Leuk Lymphoma; 2000 Jul; 38(3-4):335-43. PubMed ID: 10830740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for central nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysis.
    Keldsen N; Michalski W; Bentzen SM; Hansen KB; Thorling K
    Acta Oncol; 1996; 35(6):703-8. PubMed ID: 8938217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology.
    Márky I; Björk O; Forestier E; Jónsson OG; Perkkiö M; Schmiegelow K; Storm-Mathiesen I; Gustafsson G;
    J Pediatr Hematol Oncol; 2004 Sep; 26(9):555-60. PubMed ID: 15342981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.
    van Besien K; Ha CS; Murphy S; McLaughlin P; Rodriguez A; Amin K; Forman A; Romaguera J; Hagemeister F; Younes A; Bachier C; Sarris A; Sobocinski KS; Cox JD; Cabanillas F
    Blood; 1998 Feb; 91(4):1178-84. PubMed ID: 9454747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence of secondary central nervous system involvement in patients with non-Hodgkin's lymphoma as detected by 18F-FDG PET/CT.
    Akkas BE; Vural GU
    Nucl Med Commun; 2013 Jan; 34(1):50-6. PubMed ID: 23111376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy.
    Bokstein F; Lossos A; Lossos IS; Siegal T
    Leuk Lymphoma; 2002 Mar; 43(3):587-93. PubMed ID: 12002763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of pediatric non-Hodgkin's lymphoma.
    Blay JY; Louis D; Bouffet E; Thiesse P; Biron P; Favrot MC; Brunat-Mentigny M; Philip T
    Blood Rev; 1991 Jun; 5(2):90-7. PubMed ID: 1912759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrathecal chemotherapy in lymphomatous meningitis.
    Canova F; Marino D; Trentin C; Soldà C; Ghiotto C; Aversa SM
    Crit Rev Oncol Hematol; 2011 Aug; 79(2):127-34. PubMed ID: 20696592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience.
    Zinzani PL; Magagnoli M; Frezza G; Prologo G; Gherlinzoni F; Bendandi M; Albertini P; Babini L; D'Alessandro R; Tura S
    Leuk Lymphoma; 1999 Feb; 32(5-6):571-6. PubMed ID: 10048430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.